Offering superior diagnostic accuracy to conventional imaging in prostate cancer (PCa), Gallium-68 labeled PSMA (<sup>68</sup>Ga-PSMA) positron emission tomography/computed tomography (PET/CT) is considered the new standard of care in PCa management. This evidence concerns the gene FOLH1 and Familial prostate cancer.